Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481818 | 0.81 | NOTUM (0.49) | GPR119KDM4ENPC1MEN1KMT2A | |
| SCHEMBL5207026 | 0.79 | GPR119 (0.50) | GPR119MEN1KMT2AL3MBTL1 | |
| SCHEMBL6916048 | 0.78 | NPC1 (0.59) | NPC1MEN1KMT2AADRA1AADRA1B | |
| SCHEMBL28437453 | 0.77 | HDAC3 (0.49) | NPC1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8219392 | 0.76 | ADRB1 (0.49) | ADRA1AADRA1B | |
| SCHEMBL30777649 | 0.76 | ADRB1 (0.49) | ADRA1AADRA1B | |
| SCHEMBL21225500 | 0.74 | GPR119 (0.56) | GPR119KDM4ENPC1MEN1KMT2A | |
| SCHEMBL7567842 | 0.71 | NPC1 (0.43) | NPC1ADRA1AADRA1BATML3MBTL1 | |
| SCHEMBL109178 | 0.69 | TSHR (0.50) | NPC1MEN1KMT2AADRA1AADRA1B | |
| SCHEMBL30111657 | 0.69 | TSHR (0.50) | NPC1MEN1KMT2AADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867220-B2 | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-15 | — | — | US | disclosed |
| US-20030040530-A1 | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them | SANOFI-AVENTIS (FR) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040530-A1 | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them | CNR1, CORO1C, CBR1 | MYC 1151/4885GPR119 1715/4885KDM4E 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.